François Martelet

Directeur Technique/Scientifique/R&D chez SCANDION ONCOLOGY A/S

Profil

Dr. François R.
Martelet is a Chief Medical Officer at Scandion Oncology A/S, an Independent Director at Novigenix SA and a Senior Advisor at Ennovance Capital LLC.
He is on the Board of Directors at Novigenix SA. Dr. Martelet was previously employed as a Chief Executive Officer by Vivesto AB, a Chief Executive Officer & Executive Director by NetScientific Plc, a Chief Executive Officer by Topotarget A/S, a President & Chief Executive Officer by AVAX Technologies, Inc., a Vice President & Global Franchise Head-Oncology by Merck & Co., Inc., a Head-Regional Pharma by Novartis AG, a Chairman by Glycotest, Inc., a Chairman by ProAxsis Ltd., a Senior Vice President-International Operations by Stallergenes SAS, and a Chairman by Vortex BioSciences, Inc. He received his graduate degree from Burgundy School of Business, an MBA from the University of Dijon and a doctorate degree from the University of Dijon.

Postes actifs de François Martelet

Sociétés	Poste	Début
SCANDION ONCOLOGY A/S	Directeur Technique/Scientifique/R&D	-
Ennovance Capital LLC	Corporate Officer/Principal	27/01/2010
Novigenix SA	Directeur/Membre du Conseil	18/06/2019

Anciens postes connus de François Martelet

Sociétés	Poste	Fin
VIVESTO AB	Directeur Général	21/07/2022
EMV CAPITAL PLC	Directeur Général	30/04/2019
TOPOTARGET A/S	Directeur Général	30/08/2012
AVAX TECHNOLOGIES, INC.	Directeur Général	01/01/2009
MERCK & CO., INC.	Corporate Officer/Principal	01/12/2006